drugset / Trial / NCT07451054
CD45BE-HSPC + CART-45 Cells
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a phase 1, open-label, dose-finding study to assess the safety, feasibility, pharmacokinetics and preliminary efficacy of autologous base edited anti-CD45 CAR T cells (referred to as "CART-45 cells") following an autologous transplant of CD45 base edited hematopoietic stem and progenitor cells (referred to as "CD45BE-HSPC") in patients with relapsed or refractory hematologic malignancies.
Timeline
- Start
- 2026-07
- Primary completion
- 2051-07
- Completion
- 2051-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CART-45 cells | Cell therapy | — | — |
| Subject | CD45BE-HSPC | Cell therapy | — | — |